Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis.

Doshi, Bhavya S; Witmer, Char M

Doshi, Bhavya S; Witmer, Char M.

Affiliation

Doshi BS; Division of Hematology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Witmer CM; Department of Pediatrics, University of Pennsylvania, Philadelphia, PA, USA.

Haemophilia ; 27(4): e551-e553, 2021 Jul.

Article in En | MEDLINE | ID: mdl-33866659

Subject(s)

Antibodies, Bispecific; Hemophilia A; Antibodies, Bispecific/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Factor VIII; Hemophilia A/drug therapy; Humans

Key words

emicizumab; haemophilia A; immune tolerance; inhibitor; recurrence

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antibodies, Bispecific / Hemophilia A Limits: Humans Language: En Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Antibodies, Bispecific / Hemophilia A Limits: Humans Language: En Year: 2021 Type: Article